Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: Pioneers & pathfinders: 10 years of frontiers in medicine.

Frontiers in medicine·2025
Same author

Association between vitamin D and diabetic neuropathy in a nationally representative sample: results from 2001-2004 NHANES.

Diabetic medicine : a journal of the British Diabetic Association·2011
Same author

Ethnic differences in the relationship of prediabetes with the presence of target-organ disease.

Diabetes & metabolism·2011
Same author

Patient safety systems in the primary health care of diabetes—a story of missed opportunities?

Diabetic medicine : a journal of the British Diabetic Association·2010
Same author

Telomere length and adiposity in a racially diverse sample.

International journal of obesity (2005)·2009
Same author

Commentary on the association of polychlorinated biphenyls with hypertension.

Environmental research·2008
Same journal

Optimizing reporting and outreach for surveillance and risk-reducing surgeries for cancer genetic predisposition: Findings of a workshop organized by the International Cascade Consortium.

Public health genomics·2026
Same journal

Key outcomes from a stakeholder workshop on genomic newborn screening: recommended next steps for the integration of genomics into public health programs.

Public health genomics·2026
Same journal

The IMPACT-FH Renewal Protocol: Evaluating FH Cascade Testing Implementation in Primary Care through a Pragmatic Trial, Economic Evaluation, and Mixed-Methods Sustainability Assessment.

Public health genomics·2026
Same journal

Hereditary Hemochromatosis and Hypertrophic Cardiomyopathy as Tier 1 Genomic Conditions: Implications for Adult Population Genomic Screening.

Public health genomics·2026
Same journal

Family Leaders Navigate Burden to Communicate Risk During Cascade Screening after Sudden Cardiac Death in the Young.

Public health genomics·2026
Same journal

Adolescent and Young Adult Perspectives on Receiving Pathogenic or Likely Pathogenic Results in a Prospective Genomic Screening Clinical Trial.

Public health genomics·2026
See all related articles

Related Experiment Video

Updated: May 7, 2026

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages
08:26

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages

Published on: February 23, 2024

Racial differences in attitudes toward personalized medicine.

V A Diaz1, A G Mainous, J K Gavin

  • 1Department of Family Medicine, Medical University of South Carolina, Charleston, S.C., USA.

Public Health Genomics
|October 2, 2013
PubMed
Summary
This summary is machine-generated.

Racial disparities exist in personalized medicine acceptance. Non-Hispanic Black individuals reported more concerns, potentially linked to experiences of discrimination, impacting personalized medicine adoption.

Related Experiment Videos

Last Updated: May 7, 2026

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages
08:26

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages

Published on: February 23, 2024

Area of Science:

  • Genomics and Precision Medicine
  • Health Disparities Research
  • Patient Attitudes and Beliefs

Background:

  • Patient concerns about personalized medicine may impede its widespread adoption.
  • Understanding racial differences in attitudes is crucial for equitable implementation.
  • Key variables influencing these attitudes require thorough investigation.

Purpose of the Study:

  • To assess racial disparities in attitudes toward personalized medicine.
  • To identify factors influencing patient acceptance and concerns.
  • To evaluate the impact of self-reported discrimination on these attitudes.

Main Methods:

  • Survey of 190 adults in an academic primary care setting.
  • Assessed awareness, acceptance, concerns, and benefits of personalized medicine.
  • Logistic regression analyses controlled for demographic and experiential variables.

Main Results:

  • Non-Hispanic White participants showed higher acceptance of personalized medicine compared to Non-Hispanic Black participants (94.4% vs. 81.9%).
  • Non-Hispanic Black participants expressed greater concerns regarding genetic information use, consent, discrimination, and cost.
  • Logistic regression indicated Non-Hispanic Black individuals and those reporting discrimination had significantly more concerns (OR=7.46 and OR=2.87, respectively).

Conclusions:

  • Significant racial differences in attitudes toward personalized medicine were observed.
  • Self-reported discrimination appears to be a key factor influencing concerns.
  • Further research is needed to address these disparities and promote equitable personalized medicine use.